• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
150766 162 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
, H  R: R6 y: s
( c: }. R8 d+ U+ C, \( E# Q9 f8 |2 S
! S# }) E6 ^8 ^) E  H) F& WSub-category:
. G6 V" u8 _! I) G* N4 G4 t+ b: LMolecular Targets 8 \( z8 Z6 E, k4 @( E9 h: y
  e* {0 a* L3 [4 G4 ]
5 D3 S& e! `6 D, {* f! G) c& [
Category:* e4 V/ L* {1 {3 ?8 K) \* m
Tumor Biology * J( V- k( O( I1 X( R* ^- J8 @
# P! y' m1 E5 I7 t* c: w: x
, u1 T+ m; P7 V& f0 U
Meeting:
5 o) f; W, Y2 _2011 ASCO Annual Meeting
6 f: ~1 S* |( a- X4 v! r! k. x
0 O. v8 b( p9 \* C
# ~" K; E( }5 }! V9 l, X1 ]/ xSession Type and Session Title:2 [8 q6 ^, y9 M) P8 m
Poster Discussion Session, Tumor Biology
6 l) x$ Y0 F% Z& o& S, o1 ?. H) {, w6 F) ~$ }

4 x  k$ p8 L- j. E6 k. O/ s7 FAbstract No:
2 c8 D" r' M- i+ I0 k, r8 {10517
2 H9 j* z: b. y4 k" f9 |- M/ Q4 L& U& M* M5 F
# R& i6 u# j( {- j4 V2 }/ h
Citation:2 \3 V( \) a- j+ V4 z
J Clin Oncol 29: 2011 (suppl; abstr 10517)
! C+ c1 k( s9 S, q0 p2 u. U9 T. g8 O& D1 Y7 Q

$ L; r" X# _: rAuthor(s):8 {  w3 P9 M& d7 e/ f* K
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
" B: M$ q  y0 G9 u
: ^( a- c2 `" J% J( L) C/ r
/ Q* H/ }' J+ o: p( ]
; m+ A$ f9 \% f1 r, A" OAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
. k  Y" v  u" T3 `* _+ W) X, K) f5 V% a
Abstract Disclosures- I1 B  y. A: j3 z! o, ~( I; [6 \
/ i: R, F# \# o9 a3 U- K
Abstract:
6 O! p, _+ ^" x% l9 V9 q0 N+ O4 e8 Y
$ d& Y1 Z% c) S1 m0 n! O  J
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
! U$ U6 k0 `- q, I; v
* j+ C4 c+ w* B# B; O) H2 j
. C% u( h$ S' e8 F7 x
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 : G0 |8 j1 Z: |" e) e
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

9 B* k% R0 @9 b5 D. ?化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 / _9 u* P+ _9 q7 C! a) n
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。( o, R6 @9 l: [" B# q# c3 I! G
ALK一个指标医院要900多 ...
# J1 F4 W: _! `; ~& [
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
4 z$ ^- [/ t" w5 |. O, h5 n0 p4 r- D, N2 n4 C: P: ~9 G& @
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表